GlycoMimetics Inc (STU:GKO)
€ 0.2905 -0.0145 (-4.75%) Market Cap: 19.25 Mil Enterprise Value: 5.78 Mil PE Ratio: 0 PB Ratio: 1.78 GF Score: 23/100

GlycoMimetics Inc at Jefferies Virtual London Healthcare Conference Transcript

Nov 19, 2020 / 06:45PM GMT
Release Date Price: €3.32 (-3.49%)
Wai Kit Ma
Jefferies LLC, Research Division - Equity Associate

Hello, everyone. Welcome to the Jefferies London Virtual Health Care Conference. My name is Kit Ma. I would like to introduce our next company, GlycoMimetics, and the CEO, Rachel King.

This is going to be a standard presentation format, and after the presentation, if time allows, then we'll have a Q&A session. (Operator Instructions)

So with that, let me pass it to you, Rachel.

Rachel K. King
GlycoMimetics, Inc. - President, CEO & Director

Good. Thanks, Kit, and thanks for those of you who are listening to hear more about GlycoMimetics. Let me begin by making reference to the fact that I will be making forward-looking statements today, so I refer you to our regulatory filings for details.

I'd like to start by highlighting some of the key attributes of our late-stage pipeline and some of the upcoming catalysts that we have. Our most advanced program is uproleselan, which is currently enrolling in a Phase III trial in relapsed and refractory leukemia. This

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot